FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21- 2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 HKRI Taikoo Hui Shanghai, PRC 上海市方达律师事务所 关于诺诚健华医药有限公司（InnoCare Pharma Limited） 法律意见书 致：诺诚健华医药有限公司（InnoCare Pharma Limited） 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据诺诚健华医药有限公司（InnoCare Pharma Limited） （以下简称"诺诚健华"、"公司"或"上市公司"）的委托，本所担任诺诚健华 2024 年科创板限制性股票激励计划项目（以下简称"本激励计划"）的特聘专项法律顾 问，就本激励计划项下向激励对象授予预留限制性股票（以下简称"本次授予"或 "预留授予"）的有关事项出 ...

Core Viewpoint - The company announced the completion of the first patient dosing in a registration clinical trial for its novel BCL2 inhibitor, mesutoclax (ICP-248), aimed at treating BTK inhibitor-treated mantle cell lymphoma (MCL) [1][2] Group 1: Product Development - Mesutoclax is a new oral, highly selective BCL2 inhibitor that targets the BCL2 protein, which is crucial in the apoptosis pathway and is linked to various malignant hematological tumors [1] - The unique mechanism of action of mesutoclax allows it to restore programmed cell death in tumor cells, demonstrating potential efficacy in treating MCL, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS) [1] - The registration clinical trial aims to evaluate the safety and efficacy of mesutoclax in patients with MCL who have previously been treated with BTK inhibitors, addressing a significant unmet need in this aggressive form of B-cell non-Hodgkin lymphoma [1] Group 2: Company Strategy - The co-founder, chairman, and CEO of the company expressed optimism that mesutoclax could provide new treatment hope for lymphoma patients and emphasized the commitment to accelerate its clinical development for both Chinese and global markets [2]

Investment Rating - The report maintains a "Buy" rating for the blood cancer drug industry [3][6]. Core Insights - The blood cancer market is expanding due to innovative therapies, with significant advancements in precision diagnosis, prognosis stratification, and targeted therapies such as CAR-T and TCE, leading to improved patient survival and quality of life [5][8]. - The number of patients with blood cancer who have survived for five years or more is approximately 4 million globally, which is three times the number of new patients, indicating a growing market for long-term treatments [5][13]. - The high cost of blood cancer drugs and the emergence of blockbuster products are driving market growth, with several drugs expected to exceed $10 billion in sales by 2024 [5][17]. Summary by Sections 1. Blood Cancer Market Expansion - The proportion of new blood cancer patients is less than 10% of all new cancer cases, with a steady increase in incidence rates [8]. - Blood cancer patients have a long survival period, resulting in a large population of existing patients [13]. - The high cost of blood cancer treatments contributes to the frequent emergence of blockbuster drugs [17]. 2. Clinical Diagnosis and Treatment of Blood Cancer - Blood cancers are classified based on cell origin, differentiation, and affected sites, including leukemia, lymphoma, and multiple myeloma [19][20]. - Treatment for acute leukemia primarily involves chemotherapy or targeted combination therapies to improve survival rates [24]. - Lymphoma treatment varies by subtype, with Rituximab being a cornerstone therapy [23]. - Multiple myeloma treatment focuses on CD38 monoclonal antibodies, with ongoing exploration of solutions for relapsed and refractory cases [23]. 3. Analysis of Popular Targets and Therapies - The BTK field is seeing intense competition, with new products emerging to address resistance issues [5]. - The BCL-2 area is advancing with differentiated designs and optimized dosing strategies [5]. - The BCR-ABL TKI domain is witnessing the introduction of third-generation inhibitors that show superior efficacy [5]. 4. Company Profiles - BeiGene is focusing on a comprehensive product matrix to cover CLL/SLL indications [5]. - Innovent Biologics is building a diversified product portfolio centered around Oubreti [5]. - Ascentage Pharma is developing third-generation BCR-ABL inhibitors and BCL-2 inhibitors to create competitive advantages [5]. - Diligent Pharma is innovating with a globally first high-selectivity JAK1 inhibitor and a dual-target LYN/BTK inhibitor [5]. 5. Investment Recommendations - The blood cancer sector presents numerous investment opportunities due to its complexity and the variety of treatment subfields [5]. - The long survival cycle of blood cancer patients and the high costs of drug treatments indicate a significant market potential [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 A股代码：688428 A股简称：诺诚健华 公告编号：2025-034 港股代码：09969 港股简称：诺诚健华 诺诚健华医药有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 诺诚健华医药有限公司（以下简称"诺诚健华"或"公司"）于2025年8月20日在公司会议室以现场会议结 合通讯方式召开董事会。会议应出席董事7人，实际出席董事7人，董事会主席Jisong Cui（崔霁松）博 士担任会议主席。会议的召集、召开、表决程序符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 二、董事会会议审议情况 （一）审议通过《根据2024年科创板限制性股票激励计划向激励对象授予预留限制性股票》的议案 根据《上市公司股权激励管理办法》《2024年科创板限制性股票激励计划（草案）》及其摘要的相关规 定和公司2024年第一次临时股东大会（股东特别大会）的审议批准及授权，董事会认为公司2024年科创 板限制性股票激励计划规定的预留授予条 ...

Core Viewpoint - Nocera Biopharma (688428) reported a significant increase in revenue and a reduction in net loss for the first half of 2025, indicating improved operational performance and profitability metrics [1]. Financial Performance - Total revenue for the first half of 2025 reached 731 million yuan, a year-on-year increase of 74.26% compared to 420 million yuan in the same period of 2024 [1]. - The net loss attributable to shareholders was 30.09 million yuan, which is an improvement of 88.51% from a loss of 26.2 million yuan in the previous year [1]. - The gross margin increased to 89.51%, up 4.48% year-on-year, while the net margin improved to -4.87%, a significant increase of 92.37% [1]. - Total expenses (selling, administrative, and financial) amounted to 282 million yuan, accounting for 38.5% of revenue, a decrease of 15.49% year-on-year [1]. Cash Flow and Assets - Operating cash flow per share improved to -0.04 yuan, an increase of 78.12% year-on-year [1]. - The company’s cash and cash equivalents showed a slight increase of 0.47% to 6.981 billion yuan [3]. - Accounts receivable rose by 39.76% to 392 million yuan, attributed to increased sales of the drug Aobutini [3]. Investment and R&D - The company is focusing on strategic collaborations, including a partnership with West Lake University for innovative drug development [19]. - Nocera Biopharma is integrating AI technology into drug discovery and clinical development processes to enhance operational efficiency [19][20]. Market Position and Fund Holdings - The largest fund holding Nocera Biopharma shares is the Fortune Precision Medical Mixed A fund, which holds 12.58 million shares [18]. - The company has seen a mixed response from funds, with some increasing their holdings while others have reduced their positions [18].

诺诚健华(09969)发布公告，于2025年8月20日，公司根据2023年股权激励计划授予三名承授人21万份受 限制股份单位，相当于公司于本公告日期已发行股份总数的约0.01%。 ...

智通财经APP讯，诺诚健华(09969)发布公告，于2025年8月20日，公司根据2023年股权激励计划授予三 名承授人21万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.01%。 ...

Core Viewpoint - 诺诚健华 has announced the initial grant of restricted shares under its 2024 RMB Share Incentive Plan, indicating a commitment to incentivize key personnel and align their interests with shareholders [1] Group 1: Share Incentive Plan - The company granted a total of 9.8702 million restricted shares to 79 incentive recipients, representing approximately 0.56% of the total issued shares as of December 17, 2024 [1] - Following the initial grant, the board has confirmed that the conditions for reserved grants have been met, deciding to grant a total of 2.4676 million restricted shares to 91 incentive recipients on August 20, 2025, which will account for about 0.14% of the total issued shares as of the announcement date [1]

InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 茲載列本公司於上海證券交易所網站刊登之《董事會決議公告》、《2024年科創 板限制性股票激勵計劃預留授予激勵對象名單（截至預留授予日）》、《董事會 薪酬委員會關於公司2024年科創板限制性股票激勵計劃預留授予日激勵對象名 單的核查意見》、《上海市方達律師事務所關於諾誠健華醫藥有限公司(InnoCare Pharma Limited) 2024年科創板限制性股票激勵計劃預留授予相關事項的法律意 見書》及《上海榮正企業諮詢服務（集團）股份有限公司關於諾誠健華醫藥有限 公司2024年科創板限制性股票激勵計劃預留授予事項之獨立財務顧問報告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 根據2023年股權激勵計劃 授予受限制股份單位 根據上市規則第17.06A條，董事會宣佈於2025年8月20日，本公司根據2023年股 權激勵計劃授予三名承授人210,000份受限制股份單位，相當於本公司於本公 告日期已發行股份總數的約0.01%。 授予受限制股份單位的詳情 授予承授人受限制股份單位的詳情如下： 授出日期： 2025年8月20日 購買價： 每股香港股份0.178美元（約1.39港元） – 1 – 承授人及獲授受限制股份 單位的數目： 授予三名僱員參與者（其中包括本公司一名關連 人士）210,000份受限制股份單位，具體分配如下： ‧ Charles Zhou先 生（投 資 者 關 係 及 業 務 發 展 副 總監及本公司董事兼行政總 ...